Please assess the completion status of the following clinical trial:

Trial Title: Partnership for Research on Ebola VACcinations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent/assent~* Age greater than or equal to 1 year~* Planned residency in the area of the study site for the next 12 months~* Willingness to comply with the protocol requirements~Exclusion Criteria:~* Fever greater than 38º Celsius~* History of EVD (self-report)~* Pregnancy (a negative urine pregnancy test is required for females of child-bearing potential, i.e., females who have experienced menarche or who are aged 14 years and older)~* Positive HIV test for participants less than 18 years of age~* Reported current breast-feeding~* Prior vaccination against Ebola (self-report)~* Any vaccination in the past 28 days or planned within the 28 days after randomization (initial vaccination)~* In the judgement of the clinician, any clinically significant acute/chronic condition that would limit the ability of the participant to meet the requirements of the study protocol~Inclusion Criteria for Revaccination Post 12 Month Visit:~* Participants who received the placebo~* Participants who received an incomplete Ad26.ZEBOV/MVA-BN-Filo vaccine strategy~Temporary Exclusion Criteria for Revaccination Post 12 Month Visit:~* Fever greater than 38º Celsius~* Pregnancy (a negative urine pregnancy test is required for females of child-bearing potential, i.e., females who have experienced menarche or who are aged 14 years and older)~* Reported current breast-feeding (self-report)~* Any vaccination in the past 28 days or planned within the 28 days after trial vaccination~Exclusion Criteria for Revaccination Post 12 Month Visit:~* EVD notified in the electronic case report form~* For minor participants: change in HIV status since enrollment (self-report)~* Previous Ebola vaccination outside of the study including incomplete vaccine strategies~* Known medical history or significant risk factors for a thrombotic and/or thrombocytopenic event (for participants who will receive the Ad26.ZEBOV or MVA-BN-Filo vaccine)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost (Type: EXPERIMENTAL): Participants will receive the Ad26.ZEBOV (rHAd26) vaccine at Day 0 followed by an MVA-BN-Filo (MVA) boost at Day 56.
- Placebo (0.5 mL) (Type: PLACEBO_COMPARATOR): Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.
- rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost (Type: EXPERIMENTAL): Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by a placebo boost at Day 56.
- rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost (Type: EXPERIMENTAL): Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by an rVSV boost at Day 56.
- Placebo (1 mL) (Type: PLACEBO_COMPARATOR): Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete